Velcade Now Approved in Combination for Untreated Mantle Cell Lymphoma

According to the manufacturer, Velcade (bortezomib) has been approved by the US FDA in combination with other drugs for the treatment of patients with previously untreated mantle cell lymphoma (MCL).

Velcade has been an approved treatment for relapsed or refractory MCL since 2006. It is also approved for patients with multiple myeloma.

This newest indication means that it can be administered as part of what is now being called the VcR-CAP regimen, but over the summer was called the VR-CAP regimen.

The FDA has based approval on results of the LYM-3002 trial, which recruited patients with previously untreated MCL and randomized them to receive either standard therapy-- which is the familiar combination chemotherapy regimen R-CHOP -- or VR-CAP, which is simply the same combination as R-CHOP except you remove the vincristine and replace it with Velcade.

Results of the trial indicated that there was a higher rate of complete response in VR-CAP compared to R-CHOP (44 percent vs 34 percent) and a longer median progression-free survival (25 months vs 14 months).

However, the VR-CAP regimen in this trial also resulted in more adverse events and was associated with higher toxicity than R-CHOP.

Source: Healio

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap